

SIXTH SUPPLEMENT DATED 5 MARCH 2021

TO CREDIT SUISSE INTERNATIONAL REGISTRATION DOCUMENT DATED 8 JULY 2020 AND THE PROSPECTUSES LISTED IN SCHEDULE 1

This supplement (the “**Sixth Supplement**”) dated 5 March 2021 supplements the Registration Document dated 8 July 2020 and approved by the *Commission de Surveillance du Secteur Financier* (the “**CSSF**”) on 8 July 2020 (the “**Registration Document**”), and the prospectuses listed in Schedule 1 hereto, and constitutes the sixth supplement to the Registration Document for the purposes of Article 10(1) and Article 23(5) of Regulation (EU) 2017/1129. This Sixth Supplement should be read in conjunction with the Registration Document, the first supplement to the Registration Document dated 21 September 2020 (the “**First Supplement**”), the second supplement to the Registration Document dated 4 November 2020 (the “**Second Supplement**”), the third supplement to the Registration Document dated 9 December 2020 (the “**Third Supplement**”), the fourth supplement to the Registration Document dated 23 December 2020 (the “**Fourth Supplement**”), and the fifth supplement to the Registration Document dated 20 January 2021 (the “**Fifth Supplement**”) (collectively, the “**Existing Supplements**”), including the documents incorporated by reference therein. The terms used in this Sixth Supplement have the same meaning as the terms used in the Registration Document.

This Sixth Supplement has been produced to (i) incorporate by reference the Form 6-K Dated 18 February 2021 (as defined below) and (ii) update the sections headed “5. Change” (page 21) and “8. Legal and Arbitration Proceedings” (page 23) in the Registration Document.

This Sixth Supplement has been submitted for approval by the Financial Conduct Authority under Regulation (EU) 2017/1129 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018.

Document incorporated by reference

This Sixth Supplement incorporates by reference the following document:

- the Form 6-K of the Group and the Bank filed with the United States Securities and Exchange Commission on 18 February 2021 (the “**Form 6-K Dated 18 February 2021**”) which contains the Credit Suisse Earnings Release 4Q20 attached as an exhibit thereto, as indicated in the cross-reference table below (page 2).

For ease of reference, the relevant information from the Form 6-K Dated 18 February 2021 can be found on the following pages of the document:

Section Heading	Sub-heading	Page(s) of the PDF file
Form 6-K Dated 18 February 2021		
Form 6-K	Cover Page	1
	Explanatory Note	2
	Forward-looking statements	2
	Group and Bank differences	3 to 4
	Selected financial data – Bank	4 to 5
	Exhibits	6
	Signatures	7
Exhibit to the Form 6-K Dated 18 February 2021 (Credit Suisse Earnings Release 4Q20)		
Earnings Release 4Q20	Cover Page	8
	Key metrics	9
	Credit Suisse	10 to 18
	Swiss Universal Bank	19 to 25
	International Wealth Management	26 to 33
	Asia Pacific	34 to 37
	Investment Bank	38 to 41
	Corporate Center	42 to 45
	Assets under management	46 to 47
	Additional financial metrics	48
	Important information	49
	Appendix	50 to 61

The information identified in the above table is incorporated by reference into, and forms part of, the Registration Document (and any information not listed in the above table but included in the document referred to in the above table is not incorporated by reference and either (a) is covered elsewhere in the Registration Document; or (b) is not relevant for investors).

A copy of the document incorporated by reference into the Registration Document can be inspected online at:

<https://www.credit-suisse.com/media/assets/corporate/docs/about-us/investor-relations/financial-disclosures/sec-filings/2020-q4-6k-group-bank-1802.pdf> (the Form 6-K Dated 18 February 2021).

Only the specified portions of such documents have been incorporated by reference into the Registration Document, and not, for the avoidance of doubt, any other parts of the websites referred to in the Registration Document, including this Sixth Supplement.

For the purposes of Art. 23(5) of the Regulation (EU) 2017/1129, this Sixth Supplement forms a constituent part of, and supplements and amends, the prospectuses listed in Schedule 1 hereto.

This Sixth Supplement has been filed with the CSSF, and copies of this Sixth Supplement and the Existing Supplements, and the documents incorporated by reference into each of the Registration Document, this

Sixth Supplement and the Existing Supplements will be available on the website of the Luxembourg Stock Exchange at www.bourse.lu and on the Issuer's website at:

<https://www.credit-suisse.com/be/en/investment-banking/financial-regulatory/international.html>

Except for the copies of the documents incorporated by reference into each of the Registration Document, this Sixth Supplement and the Existing Supplements available on the Luxembourg Stock Exchange website (www.bourse.lu), no information contained on the websites to which links have been provided is incorporated by reference in the Registration Document.

Save as disclosed in this Sixth Supplement and the Existing Supplements, no other significant new factor, material mistake or inaccuracy relating to information included in the Registration Document has arisen or been noted, as the case may be, since the publication of the Registration Document.

In accordance with Article 23(2) of Regulation (EU) 2017/1129, investors who have already agreed to purchase or subscribe for securities pursuant to the prospectuses listed in Schedule 1 hereto before this Sixth Supplement is published have the right, exercisable within two working days after the publication of this Sixth Supplement, to withdraw their acceptances, provided that the significant new factor, material mistake or material inaccuracy referred to in Article 23(1) of Regulation (EU) 2017/1129 arose or was noted before the closing of the offer period or the delivery of the securities, whichever occurs first. In connection therewith, investors should contact the Distributor (as defined in the relevant prospectus) of such securities. The final date of the right of withdrawal will be 9 March 2021.

5. Change

The first three paragraphs of the section headed "5. Change" beginning on page 21 of the Registration Document, as supplemented to the date of this Sixth Supplement, are hereby amended and restated as follows:

Apart from:

(1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" (on pages 10 to 13), "Performance" (on pages 14 to 18) and "Principal risks and uncertainties" (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 headed "I—Credit Suisse results—Operating environment" on pages 4 to 6 (pages 14 to 16 of the PDF file), "I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" on page 14 (page 24 of the PDF file) and "II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" on page 60 (page 70 of the PDF file), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph of the section headed "2020 results" on page 4 (page 11 of the PDF file) and the section headed "COVID-19 pandemic and related regulatory measures" on page 10 (page 17 of the PDF file); and
(2) as more fully described in the exhibit (Credit Suisse Earnings Release 4Q20) to the Form 6-K Dated 18 February 2021, the impairment recognised relating to York Capital Management, the litigation provisions relating to mortgage-related matters, and the net loss that Credit Suisse reported in the fourth quarter of 2020,
there has been no significant change in the financial position of CSi since 30 June 2020.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi H1 Interim Report headed "Credit Suisse International at a glance—Operating environment" (on pages 10 to 13), "Performance" (on pages 14 to 18) and "Principal risks and uncertainties" (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 headed "I—Credit Suisse results—Operating environment" on pages 4 to 6 (pages 14 to 16 of the PDF file), "I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" on page 14 (page 24 of the PDF file) and "II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" on page 60 (page 70 of the PDF file), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph of the section headed "2020 results" on page 4 (page 11 of the PDF file) and the section headed

“COVID-19 pandemic and related regulatory measures” on page 10 (page 17 of the PDF file), there has been no material adverse change in the prospects of CSi since 31 December 2019.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) “Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi’s business, operations and financial performance”, (ii) the sections of the 2020 CSi H1 Interim Report headed “Credit Suisse International at a glance—Operating environment” (on pages 10 to 13), “Performance” (on pages 14 to 18) and “Principal risks and uncertainties” (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 headed “I—Credit Suisse results—Operating environment” on pages 4 to 6 (pages 14 to 16 of the PDF file), “I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures” on page 14 (page 24 of the PDF file) and “II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments” on page 60 (page 70 of the PDF file), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph of the section headed “2020 results” on page 4 (page 11 of the PDF file) and the section headed “COVID-19 pandemic and related regulatory measures” on page 10 (page 17 of the PDF file), there has been no significant change in the financial performance of CSi since 30 June 2020 to the date of the document.

8. Legal and Arbitration Proceedings

The section headed “8. Legal and Arbitration Proceedings” beginning on page 23 of the Registration Document, as supplemented to the date of this Sixth Supplement, is hereby amended and restated as follows:

During the period of 12 months ending on the date of this Sixth Supplement, there have been no governmental, legal or arbitration proceedings which may have, or have had in the recent past, significant effects on the financial position or profitability of CSi, and the Issuer is not aware of any such proceedings being either pending or threatened, except as disclosed in the 2019 CSi Annual Report under the heading “Contingent Liabilities and Other Commitments” (Note 40 to the consolidated financial statements of CSi) on pages 127 to 128, in the 2020 CSi H1 Interim Report under the heading “Contingent Liabilities and Other Commitments” (Note 23 to the consolidated interim financial statements of CSi) on page 58, in the Credit Suisse Financial Report 3Q20 under the heading “Litigation” (Note 33 to the condensed consolidated financial statements of Credit Suisse Group AG on pages 150 to 151 (pages 160 to 161 of the PDF file) of the exhibit (Credit Suisse Financial Report 3Q20) to the Form 6-K Dated 29 October 2020), and in the Credit Suisse Earnings Release 4Q20 under the heading “Litigation” on page 5 (page 12 of the PDF file) of the exhibit (Credit Suisse Earnings Release 4Q20) to the Form 6-K Dated 18 February 2021.

Provision for litigation is disclosed in Note 29 to the consolidated financial statements on page 94 of the CSi 2019 Annual Report and in Note 23 to the consolidated interim financial statements on page 58 of the 2020 CSi H1 Interim Report.

To the extent that there is any inconsistency between (a) any statement in this Sixth Supplement or any statement or information incorporated by reference into this Sixth Supplement and (b) any statement or information in or incorporated by reference into the Registration Document as supplemented by the Existing Supplements, the statements or information in (a) above will prevail.

The Issuer takes responsibility for the Registration Document, as supplemented by this Sixth Supplement and the Existing Supplements. Having taken all reasonable care to ensure that such is the case, the information contained in the Registration Document, as supplemented by this Sixth Supplement and the Existing Supplements, is, to the best knowledge of the Issuer, in accordance with the facts and contains no omission likely to affect its import. This Sixth Supplement is not for use in, and may not be delivered to or inside, the United States.

SCHEDULE 1 – LIST OF PROSPECTUSES TO WHICH THIS SUPPLEMENT RELATES

1. Securities Note comprising part of the Trigger Redeemable and Phoenix Securities Base Prospectus dated 10 July 2020.
2. Securities Note comprising part of the Put and Call Securities Base Prospectus dated 15 July 2020.
3. Securities Note comprising part of the Reverse Convertible and Worst of Reverse Convertible Securities Base Prospectus dated 16 July 2020.
4. Securities Note comprising part of the Bonus and Participation Securities Base Prospectus dated 17 July 2020.
5. Securities Note comprising up to 1,000 Certificates linked to the Nordic Small Cap Equity Fund 14% ER Index dated 12 February 2021 GB00BMYCBF71.
6. Securities Note comprising up to 1,000 Certificates linked to the Global Energy Equity Fund 18% ER Index dated 12 February 2021 GB00BMYCBG88.